Abstract P2-08-40: Reconsidering “at risk” criteria for breast cancer recurrence in hormone positive patients: Risk stratification is still important in patients with an Oncotype Dx recurrence score ≤ 25!

Abstract

Abstract Introduction: The recent TAILORx results suggest that additional systemic chemotherapy may not be necessary in certain hormone +, HER2 -, node negative breast cancer patients with an Oncotype Dx recurrence score (ODXRS) ≤ 25. ODX is an expensive test (current list price of $4,650.00), and cost has been an impediment to its adoption in many centers throughout the world. Based on a modification of the new Magee equations (Klein ME, et al. Mod Pathol. 26[5]) we published data based on 283 patients with ODXRS's (Turner BM, et al. Mod Pathol. 28[7]), suggesting that the modified Magee equation (MME) offered a less expensive alternative to ODX testing in certain breast cancer patients. We now have outcome data suggesting that the MME along with progesterone receptor (PR), Ki-67, lymph node (LN) status, and lymphovascular invasion (LVI) status can be helpful in predicting which patients with an ODXRS ≤ 25 are more likely to recur. Methods: 248 patients with information on estrogen receptor (ER), PR, Ki-67, Her-2 status, Nottingham score, tumor size, LN status, LVI status, and an available ODXRS (2008-2018) were identified from the pathology files at the University of Rochester Medical Center. Results: All of the patients that recurred had an average modified Magee score (MMS) ≥ 14 (Table 1). Patients with LN involvement (5/43,12% ) or with LVI (5/27,19%) had a higher percentage of recurrence than patients without LN involvement (8/197, 4%) or without LVI (8/216, 4%). Patients that recurred had a significantly (p < 0.05) lower PR and higher Ki-67 than patients in the same risk class that did not recur (Table 2). Neither grade nor ER status was significantly different between patients that recurred and did not recur (Table 2). All of the patients that recurred had at least a lowered PR, higher Ki-67, LN involvement, or LVI, and most had some combination of these variables (Table 1). 8 of the 13 patients that recurred in our population (61.5%) had an ODXRS of ≤ 25. Conclusions: Risk stratification is still important in patients with an ODX score ≤ 25. The MMS along with PR, Ki-67, LN, and LVI status can be helpful in predicting patients with a higher risk of recurrence. Table 1:Recurrence dataODXRSMMSType of therapy*Nodal and LVI status**Nottingham scoreER-H score***PR-H score***Ki-671119.1NONENONE6240180271319.7HNONE530015201521.6HN51209051514HNONE5270210UNKNOWN1615HLVI527018051727.2HB62701601916.3HNONE428545UNKNOWN2424.5CLVI8240105352723.9BNONE7210100352821HN527021252823.4HB528530353128.7HB82701454432.3HNONE9210607021.4****21.4****--5.9****250.7****93.4****31.4*****H = Hormone only;C = Chemo only;B = Both; ** N = Nodal involvement;L = LVI;B = Both; ***modified (Turner BM, et al. Mod Pathol. 2015;28(7):921-31); **** average Table 2:Recurrence data in specific populationsPopulation typeNGradeER*PR*Ki-67≤ 25 no recurrence2165.4249.7185.712.8**≤ 25 recurrence85.5249.4103.325.3***> 25 no recurrence267.3211.776.834.1****> 25 recurrence56.8249.042.542.0* modified (Turner BM, et al. Mod Pathol. 2015;28(7):921-31); ** n = 181; *** n = 6; **** n = 23 Citation Format: Turner BM, Sanders MAG, Soukiazian A, Soukiazian N, Hicks DG. Reconsidering “at risk” criteria for breast cancer recurrence in hormone positive patients: Risk stratification is still important in patients with an Oncotype Dx recurrence score ≤ 25! [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-40.